QT Imaging Eyes 3D Ultrasound Market with FDA-Cleared Breast Scanner

TL;DR

QTI is a high-risk bet on a promising, radiation-free breast imaging technology that needs to prove market adoption and secure significant funding to avoid becoming another medical device startup failure.

AI Summary

QT Imaging Holdings, Inc. (QTI) is a medical device company focused on developing and commercializing innovative body imaging systems using low-energy sound, specifically for breast imaging. The company has received nearly $18.1 million in financial support from the U.S. National Institutes of Health, including a $1.08 million portion of a $2.58 million grant for 'Quantitative Ultrasound Monitoring of Breast Cancer Therapies.' QTI's flagship product, the QT Breast Scanner (Breast Acoustic CT scanner), is a Class II device cleared by the FDA on August 23, 2016, under 510(k) Number K162372. This technology offers automated 3D breast imaging without ionizing radiation or compression, aiming to improve patient experience and reduce costs compared to traditional mammography. The company was formed through a business combination with GigCapital5, Inc. on March 4, 2024, and reported an aggregate market value of voting and non-voting common equity held by non-affiliates of $32.5 million as of June 30, 2025. QTI has incurred significant operating losses and has a limited operating history with its current offerings, making future profitability uncertain.

Why It Matters

QT Imaging's technology could significantly disrupt the breast cancer screening market by offering a radiation-free, compression-free alternative to mammography, potentially improving patient comfort and reducing diagnostic timelines. For investors, this represents a high-risk, high-reward opportunity in the medical device sector, competing against established players like Hologic and Siemens Healthineers. Employees and customers could benefit from a safer, more comfortable imaging experience, potentially increasing adoption rates. However, the company's limited operating history and need for additional capital pose substantial risks to its ability to achieve widespread market acceptance and profitability, impacting its long-term viability and competitive standing.

Risk Assessment

Risk Level: high — QT Imaging has incurred significant operating losses and has a limited operating history with its current offerings, making future profitability uncertain. The company's ability to successfully launch and achieve widespread market acceptance for its QT Breast Scanner is critical, and failure to do so will prevent it from generating necessary revenue. Furthermore, QTI may need to incur additional indebtedness or seek new equity/debt financings, which may not be available on acceptable terms or at all, as highlighted in the 'Risks Related to Our Business, Financial Condition and Need for Additional Capital' section.

Analyst Insight

Investors should approach QTI with extreme caution, recognizing its early-stage nature and significant capital requirements. Monitor closely for signs of increasing market adoption of the QT Breast Scanner and successful fundraising rounds. Consider a small, speculative position only if you have a high-risk tolerance and believe in the long-term potential of its novel imaging technology.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $18.1 million — Financial support from U.S. National Institutes of Health (Indicates significant external funding for technology development)
• $1.08 million — Portion of NIH grant received by QT Imaging (Part of a $2.58 million grant for breast cancer therapy monitoring)
• $32.5 million — Aggregate market value of non-affiliate common equity (As of June 30, 2025, reflecting market capitalization for public float)
• 12,042,500 — Shares of common stock outstanding (As of March 24, 2026, indicating current share count)
• 2016-08-23 — FDA 510(k) clearance date (Date QT Breast Scanner received regulatory clearance)

Key Players & Entities

• QT Imaging Holdings, Inc. (company) — Registrant and medical device company
• U.S. National Institutes of Health (regulator) — Provided nearly $18.1 million in financial support
• QT Breast Scanner (company) — Flagship Class II medical device
• FDA (regulator) — Cleared the QT Breast Scanner on August 23, 2016
• GigCapital5, Inc. (company) — Legal predecessor company in business combination
• Dr. Raluca Dinu (person) — Chief Executive Officer of QT Imaging Holdings, Inc.
• Delphinus Medical Technologies (company) — Manufacturer of the SoftVue System, a predicate device
• University of Illinois (company) — Recipient of a portion of the $2.58 million NIH grant
• University of Toronto (Sunnybrook) (company) — Recipient of a portion of the $2.58 million NIH grant
• Intertek (company) — Independent testing laboratory for QT Breast Scanner

FAQ

Risk Factors

• Limited Operating History and Profitability Concerns [high — financial]: The company has a limited operating history with its current offerings and has incurred significant operating losses. Future profitability is uncertain, which poses a substantial risk to investors.
• Dependence on Future Funding [high — financial]: The company's ability to continue its operations and commercialization efforts is dependent on its ability to secure additional funding. Without sufficient capital, its business plan may not be achievable.
• Regulatory Approval and Compliance [medium — regulatory]: The QT Breast Scanner is a Class II device cleared by the FDA. However, ongoing compliance with regulatory requirements and potential future regulatory changes could impact the company's ability to market and sell its products.
• Market Acceptance and Competition [medium — market]: The company faces competition from established medical imaging providers. Market acceptance of its novel technology, which differs from traditional mammography, is crucial for commercial success.
• Commercialization Challenges [medium — operational]: The company is in the process of commercializing its QT Breast Scanner. Challenges in manufacturing, sales, marketing, and distribution could hinder its ability to generate revenue.

Industry Context

The medical imaging industry is characterized by continuous innovation, driven by the need for more accurate, less invasive, and cost-effective diagnostic tools. Companies are developing technologies that reduce radiation exposure, improve patient comfort, and enhance diagnostic capabilities. The breast imaging segment, in particular, is seeing advancements aimed at improving early detection rates and reducing false positives/negatives compared to traditional mammography.

Regulatory Implications

As a medical device company, QT Imaging is subject to stringent FDA regulations. The 510(k) clearance for its QT Breast Scanner is a significant hurdle overcome, but ongoing compliance with manufacturing standards, post-market surveillance, and potential future regulatory changes are critical for sustained market access and growth.

What Investors Should Do

1. Monitor revenue growth and commercialization progress.
2. Assess cash burn rate and future funding needs.
3. Evaluate competitive landscape and market adoption.

Key Dates

• 2012-01-01: Formation of QT Ultrasound LLC — Marks the origin of the company's focus on developing innovative body imaging systems using low-energy sound.
• 2016-08-23: FDA 510(k) clearance for QT Breast Scanner — Indicates regulatory approval for the company's flagship product, a critical step for commercialization.
• 2024-03-04: Completion of Business Combination with GigCapital5, Inc. — The company became QT Imaging Holdings, Inc., a publicly traded entity, through a SPAC merger.
• 2025-06-30: Aggregate market value of non-affiliate common equity reported — Provides an indication of the company's market capitalization as of a specific date.

Glossary

510(k)

A premarket notification submitted to the U.S. Food and Drug Administration (FDA) to demonstrate that a medical device is at least as safe and effective, that is, substantially equivalent, to a legally marketed device. (Indicates that the QT Breast Scanner has received regulatory clearance to be marketed in the U.S.)

Class II Device

A classification for medical devices that are subject to General Controls and Special Controls. These devices are considered to pose a moderate to high risk. (Specifies the regulatory pathway and oversight applied to the QT Breast Scanner by the FDA.)

Business Combination

A merger or acquisition transaction where two or more companies combine into a single entity. In this case, GigCapital5, Inc. (a SPAC) merged with QT Imaging, Inc. (Explains the transaction that led to QT Imaging Holdings, Inc. becoming a publicly traded company.)

Special Purpose Acquisition Company (SPAC)

A shell company that is created to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. (GigCapital5, Inc. was a SPAC that facilitated QT Imaging's entry into the public markets.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text. The filing details the business combination that occurred on March 4, 2024, indicating a significant transition and likely a lack of directly comparable historical operating data for the current entity in prior periods.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share QTI The Nasdaq Stock Market
• $18 — The Company—with the support of nearly $18 1 million in financial support from the
• $811 thousand — uding grants to the University of Utah ($811 thousand) and the current five year grant 1RO1CA
• $2.58 million — e U.S. National Institute of Health for $2.58 million (Quantitative Ultrasound Monitoring of
• $1.08 million — nybrook) and QT Imaging, which received $1.08 million of the $2.58 million grant. 1 Table

Filing Documents

• qti-20251231.htm (10-K) — 2753KB
• ex1061amendmentno1todistri.htm (EX-10.61) — 20KB
• ex231bpmconsent.htm (EX-23.1) — 2KB
• ex311302certification1.htm (EX-31.1) — 11KB
• ex312302certification1.htm (EX-31.2) — 11KB
• ex321section13501.htm (EX-32.1) — 6KB
• ex322section13501.htm (EX-32.2) — 6KB
• qti-20251231_g1.jpg (GRAPHIC) — 14KB
• qti-20251231_g2.jpg (GRAPHIC) — 7KB
• qti-20251231_g3.jpg (GRAPHIC) — 19KB
• qti-20251231_g4.jpg (GRAPHIC) — 19KB
• 0001628280-26-020909.txt ( ) — 12722KB
• qti-20251231.xsd (EX-101.SCH) — 99KB
• qti-20251231_cal.xml (EX-101.CAL) — 98KB
• qti-20251231_def.xml (EX-101.DEF) — 523KB
• qti-20251231_lab.xml (EX-101.LAB) — 1029KB
• qti-20251231_pre.xml (EX-101.PRE) — 763KB
• qti-20251231_htm.xml (XML) — 1487KB

: Risk Factors

Item 1A: Risk Factors 34

: Unresolved Staff Comments

Item 1B: Unresolved Staff Comments 83

: Cybersecurity

Item 1C: Cybersecurity 83

: Properties

Item 2: Properties 83

: Legal Proceedings

Item 3: Legal Proceedings 83

: Mine Safety Disclosures

Item 4: Mine Safety Disclosures 84 Part II

: Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities

Item 5: Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 85

: Reserved

Item 6: Reserved 85

: Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations 85

: Quantitative and Qualitative Disclosures About Market Risk

Item 7A: Quantitative and Qualitative Disclosures About Market Risk 101

: Financial Statements and Supplementary Data

Item 8: Financial Statements and Supplementary Data F- 1

: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 111

: Controls and Procedures

Item 9A: Controls and Procedures 111

: Other Information

Item 9B: Other Information 112

: Disclosure Regarding Foreign Jurisdictions that Prevent Inspection

Item 9C: Disclosure Regarding Foreign Jurisdictions that Prevent Inspection 112 Part III

: Directors, Executive Officers and Corporate Governance

Item 10: Directors, Executive Officers and Corporate Governance 113

: Executive Compensation

Item 11: Executive Compensation 122

: Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12: Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 132

: Certain Relationships and Related Transactions, and Director Independence

Item 13: Certain Relationships and Related Transactions, and Director Independence 134

: Principal Accountant Fees and Services

Item 14: Principal Accountant Fees and Services 138 Part IV

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 139

: Form 10-K Summary

Item 16: Form 10-K Summary 144

Signatures

Signatures 145 i Table of Contents CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS This annual report contains forward-looking statements. All statements, other than statements of present or historical fact included in or incorporated by reference in this annual report, regarding future financial performance of QT Imaging Holdings, Inc (the "Company," "we," "our," "us" or "QT Imaging"), as well as the Company's strategy, future operations, financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this annual report, the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management's current expectations, assumptions, hopes, beliefs, intentions and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. The Company cautions you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company, incident to its business. These forward-looking statements are based on information available as of the date of this annual report, and current expectations, forecasts and assumptions, and involve a number of risks and uncertainties. Accordingly, forward-looking statements in this annual report and in any document incorporated herein by reference should not be relied upon as representing the Company's views as of any subsequent date, and the Company does not undertake any obligation to update forward-looking statement

: Business

Item 1: Business The following discussion reflects the business of the Company. In this section, "we," "us," "our," "the Company" or "QT Imaging" below generally refers to QT Imaging Holdings, Inc. and its subsidiaries. Background of the Business Combination On December 8, 2022, GigCapital5, Inc. (" GigCapital5 "), our legal predecessor company and a special purpose acquisition company which was incorporated in Delaware in 2021, entered into the Business Combination Agreement with its wholly owned subsidiary, QTI Merger Sub, Inc. (" Merger Sub "), and QT Imaging, Inc. When the transactions contemplated by the Business Combination Agreement (the " Business Combination ") closed on March 4, 2024, Merger Sub merged with and into QT Imaging, Inc. with QT Imaging, Inc. the surviving company in such merger, and after giving effect to the Business Combination, QT Imaging, Inc. became a wholly owned subsidiary of GigCapital5, which was renamed as QT Imaging Holdings, Inc. QT Imaging, Inc. was incorporated in Delaware on December 31, 2020 by converting from its predecessor, QT Ultrasound LLC (" QT Ultrasound "), which was a limited liability company formed in 2012 to focus on the research, development, and commercialization of innovative body imaging systems using low energy sound. On that date, QT Ultrasound changed its name from QT Ultrasound LLC to QT Imaging, Inc. and revoked the limited liability company election status by the incorporation. QT Imaging is headquartered in Novato, California. Overview A Novel Body Imaging Technology The Company—with the support of nearly $18 1 million in financial support from the U.S. National Institutes of Health—has developed a novel, comprehensive body imaging technology designed to produce high-resolution volumetric images of breast tissue using low-energy transmitted sound. The technology is based on ultra-low frequency transmitted and reflected sound waves and utilizes a proprietary sound back-scatter design together with

View Full Filing

View this 10-K filing on SEC EDGAR